Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
05 05 2022
Historique:
received: 01 12 2020
revised: 30 01 2021
accepted: 18 02 2021
pubmed: 12 3 2021
medline: 10 5 2022
entrez: 11 3 2021
Statut: ppublish

Résumé

Results of previous studies of abdominal adiposity and risk of vascular-metabolic mortality in Hispanic populations have been conflicting. We report results from a large prospective study of Mexican adults with high levels of abdominal adiposity. A total of 159 755 adults aged ≥35 years from Mexico City were enrolled in a prospective study and followed for 16 years. Cox regression, adjusted for confounders, yielded mortality rate ratios (RRs) associated with three markers of abdominal adiposity (waist circumference, waist-hip ratio, and waist-height ratio) and one marker of gluteo-femoral adiposity (hip circumference) for cause-specific mortality before age 75 years. To reduce reverse causality, deaths in the first 5 years of follow-up and participants with diabetes or other prior chronic disease were excluded. Among 113 163 participants without prior disease and aged 35-74 years at recruitment, all adiposity markers were positively associated with vascular-metabolic mortality. Comparing the top versus bottom tenth of the sex-specific distributions, the vascular-metabolic mortality RRs at ages 40-74 years were 2.32 [95% confidence interval (CI) 1.84-2.94] for waist circumference, 2.22 (1.71-2.88) for the waist-hip ratio, 2.63 (2.06-3.36) for the waist-height ratio, and 1.58 (1.29-1.93) for hip circumference. The RRs corresponding to each standard deviation (SD) higher usual levels of these adiposity markers were 1.34 (95% CI 1.27-1.41), 1.31 (1.23-1.39), 1.38 (1.31-1.45), and 1.18 (1.13-1.24), respectively. For the markers of abdominal adiposity, the RRs did not change much after further adjustment for other adiposity markers, but for hip circumference the association was reversed; given body mass index and waist circumference, the RR for vascular-metabolic mortality for each one SD higher usual hip circumference was 0.80 (0.75-0.86). In this study of Mexican adults, abdominal adiposity (and in particular the waist-height ratio) was strongly and positively associated with vascular-metabolic mortality. For a given amount of general and abdominal adiposity, however, higher hip circumference was associated with lower vascular-metabolic mortality.

Identifiants

pubmed: 33693634
pii: 6163117
doi: 10.1093/eurjpc/zwab038
pmc: PMC9071366
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

730-738

Subventions

Organisme : Medical Research Council
ID : MR/R007764/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00017/2
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/13/1/30181
Pays : United Kingdom
Organisme : Breast Cancer Now
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Clin Chem. 2002 Sep;48(9):1627-9
pubmed: 12194959
Nat Rev Dis Primers. 2017 Jun 15;3:17034
pubmed: 28617414
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Atherosclerosis. 2006 Dec;189(2):420-7
pubmed: 16442545
Diabetes Care. 2016 Nov;39(11):1996-2003
pubmed: 27733421
Nat Rev Endocrinol. 2015 Feb;11(2):90-100
pubmed: 25365922
Stat Med. 2004 Jan 15;23(1):93-104
pubmed: 14695642
PLoS One. 2020 Nov 5;15(11):e0241841
pubmed: 33152746
N Engl J Med. 2016 Nov 17;375(20):1961-1971
pubmed: 27959614
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Obesity (Silver Spring). 2018 Aug;26(8):1372-1380
pubmed: 30070038
J Gerontol A Biol Sci Med Sci. 2015 Apr;70(4):503-10
pubmed: 25209254
Lancet. 1990 Mar 31;335(8692):765-74
pubmed: 1969518
Ann Intern Med. 2019 Sep 17;171(6):397-405
pubmed: 31404923
N Engl J Med. 2016 Jun 23;374(25):2430-40
pubmed: 27074389
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
Int J Epidemiol. 2006 Apr;35(2):243-9
pubmed: 16556648
PLoS Genet. 2019 Oct 24;15(10):e1008405
pubmed: 31647808
Eur J Clin Nutr. 2013 Jun;67(6):573-85
pubmed: 23511854
Lancet. 2005 Nov 5;366(9497):1640-9
pubmed: 16271645
Lancet. 2011 Mar 26;377(9771):1085-95
pubmed: 21397319
Hypertension. 2017 Apr;69(4):608-614
pubmed: 28223471
Lancet Glob Health. 2019 Oct;7(10):e1332-e1345
pubmed: 31488387

Auteurs

Louisa Gnatiuc (L)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Roberto Tapia-Conyer (R)

School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Rachel Wade (R)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
MRC Population Health Research Unit, NDPH, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.

Raúl Ramirez-Reyes (R)

School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Diego Aguilar-Ramirez (D)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

William Herrington (W)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
MRC Population Health Research Unit, NDPH, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.

Michael Hill (M)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
MRC Population Health Research Unit, NDPH, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.

Sarah Lewington (S)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
MRC Population Health Research Unit, NDPH, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.
UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Jason Torres (J)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Eirini Trichia (E)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Rory Collins (R)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Richard Peto (R)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Robert Clarke (R)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.

Pablo Kuri-Morales (P)

School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Jonathan R Emberson (JR)

Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK.
MRC Population Health Research Unit, NDPH, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK.

Jesus Alegre-Díaz (J)

School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH